On June 23rd to 26th, 2014 we will be participating once again at the Costa Rican booth #5653 promoting our products. Feel free to request a meeting if you are
We are proud to share with you that our product is in the list of 43 worldwide companies profiled in the Global HPV Testing Industry Report. The report provides separate
Virofem & Viroscreen, of Weisbaden, Germany have entered into an agreement with bioTD to distribute Citofem® in Germany, Austria and Switzerland. The company is a major force in the European market for HPV detection, and will bring its knowledge and experience to Citofem distribution.
BioTD’s CEO Robin Wiscovitch commented, “Virofem & Viroscreen is a company we have admired for many years – a true leader in innovative and cost-effective approaches to in vitro diagnostics. We are thrilled to join forces and learn from them, as well as begin our efforts in critical and demanding European markets.”
BioTD has signed an exclusive agreement for distribution of Citofem® in Portugal with LaboSphera Ltda. in 2013.
LaboSphera – produtos de laboratorio, is a Portuguese company founded by Mr. Carlos Caetano in 2004. Mr. Caetano has a recognized career path as a licenced pathologist and has a broad network of top-level colleagues in both public and private labs throughout the Iberian Peninsula.
“The executives of BioTD are people that I respect and have great esteem for; I am very positive about this agreement and look forward to doing business with them”, expressed Mr. Caetano, CEO of LaboSphera Ltda.
“We are confident LaboSphera represents our products in the most reliable manner and have established a trustworthy and long-lasting relationship with Mr. Caetano; LaboSphera serves as one of our European reference labs,” said Robin Wiscovitch, CEO, BioTD. S.A.
On September 15th, 2013, BioTD and BIODIS, a Little Rock, Arkansas based company entered into an agreement to distribute CITOFEM distribute Citofem®, in North America, India, Africa and Asia.
“Citofem® is the next generation of liquid cytology,” said Dr. Ladly Abraham, Chief Medical Officer ofBiodis. “Citofem® requires no specialized machinery, and offers the greatest value in cervical cancer screening in the world today.”
“With the talent, passion and experience Biodis has for distributing superior products and providing quick, responsive service, we believe Biodis is the ideal partner to assist us in the sales and distribution of Citofem® worldwide,” said Robin Wiscovitch, CEO, BioTD. S.A.
Gobierno declara de interés público industria de dispositivos biomédicos Comunicado de prensa Firma de Decreto se dio en la inauguración de la empresa costarricense bioTD, primera en diseñar, fabricar y